Ibrance v Kisqali: Quicker Novartis Discount Helps Cut UK NICE’s Timeline
Executive Summary
It took NICE, England’s health technology appraisal body, 84 days to say yes to Novartis’ Kisqali and almost a year to recommend Pfizer’s Ibrance. Willingness to sacrifice on price could have had a big impact on timelines.
You may also be interested in...
Ibrance Joins Rival CDK4/6 Inhibitors In English Cancer Drugs Fund
Pfizer’s Ibrance has won conditional reimbursement in England while more data is gathered to reduce some uncertainty.
Pfizer To Compromise On NICE Price For Ibrance?
NICE, the HTA for England and Wales, is poised to say no to Pfizer’s Ibrance (palbociclib), because the cost of the drug is too big in relation to its benefits. The company will likely have to come back with a patient access scheme to secure reimbursement.
Pfizer Laments Price Cut Needed To Secure Xalkori NICE Yes
Pfizer warns that price cuts are unsustainable as UK HTA NICE gives provisional backing to Xalkori and Novartis' Afinitor. The drug makers had offered additional, undisclosed price cuts for their cancer therapies.